Medical Research Clinical Trial

Contributing to advancements in the field of Dermatology

Doctors Poulos and Fisher, and the entire team of dermatologists at Kingsway Dermatology strongly believe that being at the forefront of medical research is a vital part of their practice.

In keeping with our mission to provide outstanding patient care, Kingsway Clinical Research was established in 2014, as a division of Kingsway Dermatology, that specializes in clinical trials in collaboration with Probity Medical Research.

Our goal is to help bring safe and effective cutting edge treatments to our patients. This work allows our patients access to medications, sometimes years ahead of the commercial launch. It also allows our patients access to medications that may not be covered under insurance programs.

Why choose Kingsway Clinical Research?

Trusted reputation of our team of experienced, Board certified Dermatologists, with experience in clinical trials
Our research centre is interconnected with a busy dermatology clinic with a large and non-transient patient population
Conveniently located – right across the Islington subway station, 10 km from St. Joseph’s Hospital, and 12 km from Toronto Pearson International Airport
Presence of investigators while study patients are scheduled
Assurance of strictest patient confidentiality, privacy and professionalism

Access to alternative treatments & novel drugs
Taking an active role in your health care
Comprehensive medical care from overseeing physician and dedicated clinical trials staff
Opportunity to contribute to advancements in medical research
No cost on your part and compensation for travel associated with the study is available

Interested?

Join our clinical trials now for free, early access to the latest dermatology treatments! If you’re interested in helping our trusted team, please call or email us our clinical trials coordinator.

Email
carli.kdc@gmail.com

Call 416-231-0100 ext 212

Why Volunteer for Clinical Trials?

Current Trials

ATOPIC DERMATITIS

A phase 3 randomized, placebo-controlled, double-blind study to evaluate upadacitinib in combination with topical corticosteroids in adolescent and adult subjects with moderate to severe atopic dermatitis
A phase 3, multicenter, double-blind maintenance study to assess long-term safety, tolerability, and efficacy of rocatinlimab in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) (ROCKET-ASCEND)
A prospective, observational study of Canadian patients receiving dupixent for moderate to severe atopic dermatitis

ALOPECIA ARETA

PRURIGO NODULARIS

PSORIASIS

Completed Trials

ACNE

ATOPIC DERMATITIS

A phase 3, 24-week, randomized, placebo-controlled, double-blind study to assess the effect of rocatinlimab on vaccine antibody response in adult subjects with moderate-to-severe atopic dermatitis (AD) (ROCKET – VOYAGER)
A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ANB032 in the treatment of subjects with moderate to severe atopic dermatitis
An open-label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis
A phase 3 extension trial of DELTA 1 and DELTA 2 to evaluate the long-term safety of a twice-daily treatment with delgocitinib cream 20 mg/g as needed for up to 36 weeks in adult subjects with chronic hand eczema (DELTA 3)
phase 3 clinical trial to confirm efficacy and evaluate safety of twice-daily delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adult subjects with moderate to severe chronic hand eczema (DELTA 2)
A phase 3 multi-center, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis
A phase 3b randomized, double-blind, double-dummy, active controlled multi-center study assessing the efficacy and safety of abrocitinib compared with dupilumab in adult participants on background topical therapy with moderate to severe atopic dermatitis
A phase 3, double-blind, randomized, 8-week, vehicle-controlled efficacy and safety study of ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis
A phase 3 randomized, placebo-controlled, double-blind study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis
An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials
A multicenter, open-label, phase 3 study to evaluate the efficacy and safety of baricitinib in adult patients with moderate to severe atopic dermatitis
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of baricitinib in adult patients with moderate to severe atopic dermatitis
Tralokinumab monotherapy for moderate-to-severe atopic dermatitis ECZTRA 2
A randomised, double-blind, vehicle-controlled, phase IIb study to assess the efficacy and safety of topically applied DS107 cream to adults with mild to moderate atopic dermatitis
An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab clinical trials
A phase 3, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of multiple dupilumab dose regimens administered as monotherapy for maintaining treatment response in patients with atopic dermatitis
A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moderate-to-severe atopic dermatitis

PRURIGO NODULARIS

PSORIASIS

A phase 3, randomized, multicenter, double-blind, placebo- and active comparator-controlled study to evaluate the efficacy, safety, and tolerability of TAK-279 in subjects with moderate-to-severe plaque psoriasis
A phase 3, multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 654 compared with ustekinumab in subjects with moderate to severe plaque psoriasis
A long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults
A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults
A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS)
A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY)
BI 655066 (risankizumab) versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment (IMMhance)
A double-blind, randomized, parallel-group, active-control study to compare the efficacy and safety of CHS-1420 versus Humira® in subjects with chronic plaque psoriasis (PsOsim)
A single-arm study to assess the immunogenicity and safety of etanercept produced using a modified process in subjects with plaque psoriasis
A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis
Canadian Humira post marketing observational epidemiological study: Assessing effectiveness in psoriasis
A phase 3 study to evaluate the efficacy and safety of induction and maintenance regimens of brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis: AMAGINE-3

SUBCUTANEOUS ABDOMINAL FAT

VITILIGO

A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of the efficacy and safety of INCB054707 followed by an extension period in participants with vitiligo
A double-blind, vehicle-controlled, randomized withdrawal and treatment extension study to assess the long-term efficacy and safety of ruxolitinib cream in participants with vitiligo
A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of ruxolitinib cream followed by an extension period in participants with vitiligo

ALOPECIA AREATA

At Kingsway Dermatology & Cosmetic Centre in Toronto, Dr. Elena Poulos and Dr. Marnie Fisher stand out as dedicated leaders in skin health and aesthetic care, combining years of expertise as board certified dermatologists with a patient-centered approach to deliver transformative results. Together, they lead a team of like-minded dermatologists who foster a welcoming environment where education and empathy guide every patient experience.

Meet the Team

We'd love to hear from you! If you have questions, want to schedule a consultation, or just want to chat about your goals, we're here to help. Fill out the form to get started.

Company

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Phone(Required)

How can we help?(Required)

Media

Blog

Stay Informed Never miss important updates, health insights and exclusive practice news.

Privacy | Terms & Conditions | Accessibility Statement | Sitemap

COSMETIC (416) 231-0103
MEDICAL (416) 231-0100

1243 Islington Ave Unit 1000,
Etobicoke, ON M8X 1Y9

Privacy | Terms & Conditions | Accessibility Statement | Sitemap

Medical Research Clinical Trial

At Kingsway Dermatology & Cosmetic Centre, expert care means results you can trust. Your True You journey begins here. Fill out the form to get started.*

Why choose Kingsway Clinical Research?

Interested?

Why Volunteer for Clinical Trials?

Current Trials

Completed Trials

We'd love to hear from you! If you have questions, want to schedule a consultation, or just want to chat about your goals, we're here to help. Fill out the form to get started.

Media

Media

Blog

Stay Informed Never miss important updates, health insights and exclusive practice news.

At Kingsway Dermatology & Cosmetic Centre, expert care means results you can trust. Your True You journey begins here. Fill out the form to get started.*

At Kingsway Dermatology & Cosmetic Centre, expert care means results you can trust. Your True You journey begins here. Fill out the form to get started.*

Medical Research Clinical Trial

Why choose Kingsway Clinical Research?

Interested?

Why Volunteer for Clinical Trials?

Current Trials

Completed Trials

We'd love to hear from you! If you have questions, want to schedule a consultation, or just want to chat about your goals, we're here to help. Fill out the form to get started.

Media

Media

Blog

Stay Informed Never miss important updates, health insights and exclusive practice news.

Thank you!